Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

FDA approves new formulation of Abbott's Norvir

July 1, 1999

SJ-3366, a dual inhibitor of HIV reverse transcriptase and viral attachment

July 1, 1999

Team from NCI designs resistance-repellent HIV protease inhibitors

July 1, 1999

Gilead seeks approval for adefovir dipivoxil in the U.S.

July 1, 1999

Ziagen approved in Canada in combination therapy for HIV/AIDS therapy

June 30, 1999

Trimeris initiates patient selection and dosing in T-20 phase II trial

June 30, 1999

Nordic study of therapeutic immunization with rgp160 reported in The Lancet

June 28, 1999

New brominated analogue of zidovudine with significantly improved lipophilicity

June 28, 1999

HIV protease inhibitor Agenerase now available in oral solution

June 28, 1999

Tipranavir is active against 90% of HIV strains with high resistance to protease inhibitors

June 25, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...